المؤلفون: Román Ivorra, Jose A, Trallero-Araguás, Ernesto, Lopez Lasanta, Maria America, Cebrián, Laura, Lojo, Leticia, López-Muñíz, Belén

المساهمون: Institut Català de la Salut, Román Ivorra JA Reumathology Department, Hospital Politécnico y Universitario La Fe, Valencia, Spain. Trallero-Araguas E, Lopez Lasanta M Servei de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Cebrián L, Lojo L Rheumatology Department, Hospital Infanta Leonor, Madrid, Spain. López-Muñíz B Pneumology Department, Hospital Infanta Leonor, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Aprenentatge automàtic, Artritis reumatoide - Epidemiologia, Pulmons - Malalties - Epidemiologia, DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial, DISEASES::Musculoskeletal Diseases::Joint Diseases::Arthritis::Arthritis, Rheumatoid, PHENOMENA AND PROCESSES::Mathematical Concepts::Algorithms::Artificial Intelligence::Machine Learning, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence, ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales, ENFERMEDADES::enfermedades musculoesqueléticas::artropatías::artritis::artritis reumatoide, FENÓMENOS Y PROCESOS::conceptos matemáticos::algoritmos::inteligencia artificial::aprendizaje automático, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::prevalencia

وصف الملف: application/pdf

Relation: RMD Open;10(1); https://doi.org/10.1136/rmdopen-2023-003353; Román Ivorra JA, Trallero-Araguas E, Lopez Lasanta M, Cebrián L, Lojo L, López-Muñíz B, et al. Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning. RMD Open. 2024 Jan;10(1):e003353.; https://hdl.handle.net/11351/11115; 001154950300004

الاتاحة: https://hdl.handle.net/11351/11115
https://doi.org/10.1136/rmdopen-2023-003353

المؤلفون: Wilson Bautista-Molano, Liza González, Daniel Fernández-Ávila, Rosa Cardozo, Óscar Ruiz

المصدر: Biomédica: revista del Instituto Nacional de Salud, Vol 41, Iss 3, Pp 472-480 (2021)

مصطلحات موضوعية: artritis reumatoide/epidemiología, tuberculosis, riesgo, terapia biológica, Medicine, Arctic medicine. Tropical medicine, RC955-962

وصف الملف: electronic resource

Relation: https://revistabiomedica.org/index.php/biomedica/article/view/5416; https://doaj.org/toc/0120-4157

URL الوصول: https://doaj.org/article/4f9b5111f0224a42a4b7cea661836c72

المؤلفون: Bautista-Molano, Wilson, González, Liza, Fernández-Ávila, Daniel, Cardozo, Rosa, Ruiz, Óscar

المصدر: Biomedica; Vol. 41 No. 3 (2021); 472-480 ; Biomédica; Vol. 41 Núm. 3 (2021); 472-480 ; 2590-7379 ; 0120-4157

مصطلحات موضوعية: Arthritis, rheumatoid/epidemiology, tuberculosis, risk, biological therapy, artritis reumatoide/epidemiología, riesgo, terapia biológica

وصف الملف: application/pdf; text/xml

Relation: https://revistabiomedica.org/index.php/biomedica/article/view/5416/4809; https://revistabiomedica.org/index.php/biomedica/article/view/5416/4951; Smolen JS, Aletaha D, Barton A, Burmester G, Emery P, Firestein G, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https://doi.org/10.1038/nrdp.2018.1; Bautista-Molano W, Fernández-Ávila D, Jiménez R, Cardozo R, Marín A, Soler MP, Gómez O, Ruiz O. Perfil epidemiológico de pacientes colombianos con artritis reumatoide evaluados n una clínica especializada de atención integral. Reumatol Clin. 2016;12:313-8. https://doi.org/10.1016/j.reuma.2015.11.009; Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-92. https://doi.org/10.1002/art.21137; Smolen JS, Landewé RBM, Bijlsma JW, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic; and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-99 https://doi.org/10.1136/annrheumdis-2019-216655; Kauffman SH. New issues in tuberculosis. Ann Rheum Dis. 2004;63 (Suppl.2):50-6. https://doi.org/10.1136/ard.2004.028258; Zar HJ, Udwadia ZF. Advances in tuberculosis 2011-2012. Thorax. 2013;68:283-7. https://doi.org/10.1136/thoraxjnl-2012-203127; Corbett EL, Watt CJ, Walker N, Maher D, Willliams B, Raviglione M, et al. The growing burden of tuberculosis global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21. https://10.1001/archinte.163.9.1009; Raviglione M. Global tuberculosis report 2015, World Health Organization. Fecha de consulta: 9 de noviembre de 2017. Disponible en: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf; Chaparro PE, García I, Guerrero MI, León CI. Situación de la tuberculosis en Colombia, 2002. Biomédica. 2004;24(Suppl.1):102-14. https://doi.org/10.7705/biomedica.v24iSupp1.1309; López-Pérez M. Informe de evento tuberculosis en Colombia 2018. Fecha de consulta: 1 de diciembre de 2020. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/TUBERCULOSIS_2018.pdf; Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl.3):S199-S203. https://doi.org/10.1086/429998; Gómez-Reino JJ, Carmona L, Valverde VR, Martín-Mola E, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7. https://doi.org/10.1002/art.11137; O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Ann Rev Immmunol. 2013;31:475-527. https://doi.org/10.1146/annurev-immunol-032712-095939; Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, et al. Interferongamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77-87. https://doi.org/10.1164/rccm.201302-0365OC; Pai M, Denkinger CM, Kik SV, Rangaka M, Zwerling A, Oxlade O, et al. Gamma Interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3-20. https://doi.org/10.1128/CMR.00034-13; Dannenberg AM. Delayed-type hypersensitivity and cell mediated immunity in the pathogenesis of tuberculosis. Immunol Today. 1991;12:229-33. https://doi.org/10.1016/0167-5699(91)90035-R; Pérez C, Borda A. Interpretación de la PPD, fundamentos fisiopatológicos y enfoque práctico. Rev Colomb Neumol. 2007;19:11-7.; American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600; Forero E, Chalem M, Vásquez G, Jauregui E, Medina L, Pinto L, et al. Risk management for prescribing biological therapies. Rev Colomb Reumatol. 2016;23:50-67. https://doi.org/10.1016/j.rcreu.2016.02.004; Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8. https://doi.org/10.1136/ard.2009.118935; Chung TT, Ko HJ, Lau CS, Chung HY. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020;40:1-8. https://doi.org/10.1007/s00296-020-04583-8; Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006;174:736-42. https://doi.org/10.1164/rccm.200509-1516PP; López-Pérez M. Informe final. Tuberculosis, Colombia, 2014. Fecha de consulta: 29 de abril de 2016. Disponible en: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/Informe%20de%20Evento%20Epidemiolgico/Tuberculosis%202014.pdf; Zafari P, Golpour M, Hafezi N, Bashash D, Esmaeli S, Golpour M, et al. Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening. IUBMB Life. 2020;73:26-39. https://doi.org/10.1002/iub.2413; Tamborenea MN, Tate G, Mysler E, Debonis J, Schiledman A. Prevalence of positive PPD in a cohort of rheumatoid arthritis patients. Rheumatol Int. 2010;30:613-6. https://doi.org/10.1007/s00296-009-1027-z; Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Molto A, van den Bosch F, et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: A comparative study with the general population and data from the ASAS-COMOSPA Study. J Rheumatol. 2018;45:206-12. https://doi.org/10.3899/jrheum.170520; Pahal P, Sharma S. PPD Skin Test. Treasure Island (FL): Stat Pearls Publishing; 2020. Fecha de consulta: 25 de marzo de 2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK556037/; Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200. https://doi.org/10.1056/NEJM200107193450307; https://revistabiomedica.org/index.php/biomedica/article/view/5416

الاتاحة: https://revistabiomedica.org/index.php/biomedica/article/view/5416

المؤلفون: González, Liza, Cardozo, Rosa, Ruiz, Oscar Orlando

المساهمون: Bautista Molano, Wilson [https://orcid.org/0000-0003-0684-9542], Fernández-Avila, D. G. [https://orcid.org/0000-0003-1490-1822]

المصدر: Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque

مصطلحات موضوعية: Risk, Rheumatoid/epidemiology, Artritis reumatoide/epidemiología, Terapia biológica, Arthritis, Tuberculosis, Biological therapy, Riesgo

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3056::6a3c107b5f6e98495707fe0bad11aa77

Additional Titles: Frecuencia de positividad de la prueba de intradermorreacción a tuberculina en una cohorte de pacientes con artritis reumatoide

المؤلفون: Bautista-Molano, Wilson, González, Liza, Fernández-Ávila, Daniel, Cardozo, Rosa, Ruiz, Óscar

المصدر: Biomedica; Vol. 41 No. 3 (2021); 472-480; Biomédica; Vol. 41 Núm. 3 (2021); 472-480; 2590-7379; 0120-4157

مصطلحات الفهرس: Arthritis, rheumatoid/epidemiology, tuberculosis, risk, biological therapy, artritis reumatoide/epidemiología, riesgo, terapia biológica, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: https://revistabiomedica.org/index.php/biomedica/article/view/5416
https://revistabiomedica.org/index.php/biomedica/article/view/5416/4809
https://revistabiomedica.org/index.php/biomedica/article/view/5416/4951
https://revistabiomedica.org/index.php/biomedica/article/view/5416/4809
https://revistabiomedica.org/index.php/biomedica/article/view/5416/4951
*ref*/Smolen JS, Aletaha D, Barton A, Burmester G, Emery P, Firestein G, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https://doi.org/10.1038/nrdp.2018.1
*ref*/Bautista-Molano W, Fernández-Ávila D, Jiménez R, Cardozo R, Marín A, Soler MP, Gómez O, Ruiz O. Perfil epidemiológico de pacientes colombianos con artritis reumatoide evaluados n una clínica especializada de atención integral. Reumatol Clin. 2016;12:313-8. https://doi.org/10.1016/j.reuma.2015.11.009
*ref*/Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-92. https://doi.org/10.1002/art.21137
*ref*/Smolen JS, Landewé RBM, Bijlsma JW, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic
*ref*/and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-99 https://doi.org/10.1136/annrheumdis-2019-216655
*ref*/Kauffman SH. New issues in tuberculosis. Ann Rheum Dis. 2004;63 (Suppl.2):50-6. https://doi.org/10.1136/ard.2004.028258
*ref*/Zar HJ, Udwadia ZF. Advances in tuberculosis 2011-2012. Thorax. 2013;68:283-7. https://doi.org/10.1136/thoraxjnl-2012-203127
*ref*/Corbett EL, Watt CJ, Walker N, Maher D, Willliams B, Raviglione M, et al. The growing burden of tuberculosis global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21. https://10.1001/archinte.163.9.1009
*ref*/Raviglione M. Global tuberculosis report 2015, World Health Organization. Fecha de consulta: 9 de noviembre de 2017. Disponible en: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
*ref*/Chaparro PE, García I, Guerrero MI, León CI. Situación de la tuberculosis en Colombia, 2002. Biomédica. 2004;24(Suppl.1):102-14. https://doi.org/10.7705/biomedica.v24iSupp1.1309
*ref*/López-Pérez M. Informe de evento tuberculosis en Colombia 2018. Fecha de consulta: 1 de diciembre de 2020. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/TUBERCULOSIS_2018.pdf
*ref*/Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl.3):S199-S203. https://doi.org/10.1086/429998
*ref*/Gómez-Reino JJ, Carmona L, Valverde VR, Martín-Mola E, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7. https://doi.org/10.1002/art.11137
*ref*/O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Ann Rev Immmunol. 2013;31:475-527. https://doi.org/10.1146/annurev-immunol-032712-095939
*ref*/Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, et al. Interferongamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77-87. https://doi.org/10.1164/rccm.201302-0365OC
*ref*/Pai M, Denkinger CM, Kik SV, Rangaka M, Zwerling A, Oxlade O, et al. Gamma Interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3-20. https://doi.org/10.1128/CMR.00034-13
*ref*/Dannenberg AM. Delayed-type hypersensitivity and cell mediated immunity in the pathogenesis of tuberculosis. Immunol Today. 1991;12:229-33. https://doi.org/10.1016/0167-5699(91)90035-R
*ref*/Pérez C, Borda A. Interpretación de la PPD, fundamentos fisiopatológicos y enfoque práctico. Rev Colomb Neumol. 2007;19:11-7.
*ref*/American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
*ref*/Forero E, Chalem M, Vásquez G, Jauregui E, Medina L, Pinto L, et al. Risk management for prescribing biological therapies. Rev Colomb Reumatol. 2016;23:50-67. https://doi.org/10.1016/j.rcreu.2016.02.004
*ref*/Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8. https://doi.org/10.1136/ard.2009.118935
*ref*/Chung TT, Ko HJ, Lau CS, Chung HY. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020;40:1-8. https://doi.org/10.1007/s00296-020-04583-8
*ref*/Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006;174:736-42. https://doi.org/10.1164/rccm.200509-1516PP
*ref*/López-Pérez M. Informe final. Tuberculosis, Colombia, 2014. Fecha de consulta: 29 de abril de 2016. Disponible en: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/Informe%20de%20Evento%20Epidemiolgico/Tuberculosis%202014.pdf
*ref*/Zafari P, Golpour M, Hafezi N, Bashash D, Esmaeli S, Golpour M, et al. Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening. IUBMB Life. 2020;73:26-39. https://doi.org/10.1002/iub.2413
*ref*/Tamborenea MN, Tate G, Mysler E, Debonis J, Schiledman A. Prevalence of positive PPD in a cohort of rheumatoid arthritis patients. Rheumatol Int. 2010;30:613-6. https://doi.org/10.1007/s00296-009-1027-z
*ref*/Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Molto A, van den Bosch F, et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: A comparative study with the general population and data from the ASAS-COMOSPA Study. J Rheumatol. 2018;45:206-12. https://doi.org/10.3899/jrheum.170520
*ref*/Pahal P, Sharma S. PPD Skin Test. Treasure Island (FL): Stat Pearls Publishing; 2020. Fecha de consulta: 25 de marzo de 2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK556037
*ref*/Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200. https://doi.org/10.1056/NEJM200107193450307